Blue Cross Laboratories, the owner of the Meftal painkiller brand, has clarified that the adverse reaction the Indian Pharmacopoeia Commission (IPC) has flagged is a rare event. The company claims that the product's constituent, mefenamic acid, can cause adverse reactions, including eosinophilia and systemic symptoms (DRESS) syndrome.
Related Keywords
India , Japan , United Kingdom , , Pvpi Pharmacovigilance Programme , Indian Pharmacopoeia Commission , Blue Cross Laboratories , Across Laboratories , Pharmacovigilance Programme , Meftal Painkiller , Meftal , Ipc Safety Alert , Pvpi , Indian Pharmacopoeia Commission Ipc ,
comparemela.com © 2020. All Rights Reserved.